Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GLAUKOS CORPORATION

(GKOS)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 09/22 03:17:45 pm
51.84 USD   +1.79%
09/20GLAUKOS : Signs Licensing Deal With Attillaps
MT
09/20GLAUKOS : Announces Licensing Agreement with Attillaps Holdings, Inc.
BU
09/15Health Care Stocks Edge Higher Premarket Wednesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GLAUKOS CORP : Regulation FD Disclosure (form 8-K)

07/20/2021 | 08:57am EDT

Item 7.01. Regulation FD Disclosure.

On July 19, 2021, the Centers for Medicare & Medicaid Services (CMS) proposed Medicare payment rates for services furnished in both the hospital outpatient (HOPD) and Ambulatory Surgical Center (ASC) settings. The Calendar Year (CY) 2022 Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System Proposed Rule is published annually and is followed by a 60-day public comment period closing on September 17, 2021, which will culminate in CMS' release of the Final Rule, which is expected to be announced by November 2021, for implementation on January 1, 2022. The Proposed Rule is therefore subject to change. The Proposed Rule is in addition to the CMS Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule released by CMS on July 13, 2021, as discussed in a press release issued by Glaukos Corporation (Glaukos) on July 14, 2021.

The Proposed Rule and accompanying Addenda include facility fee payment rates for two new Category I Current Procedural Terminology (CPT) codes, including 669X2 for non-complex cataract extraction in combination with the insertion of an aqueous drainage device and 669X1 for complex cataract extraction in combination with the insertion of an aqueous drainage device. Category I CPT Codes 669X2 and 669X1 will replace Category III code 0191T as the primary code that hospitals and ASCs will use to seek reimbursement utilizing Glaukos' trabecular micro-bypass technologies (iStent®, iStent inject®, iStent inject W) when used as approved in combination with cataract surgery. The Proposed Rule includes a 2022 ASC facility fee payment rate for CPT codes 669X2 and 669X1 of $2,516, compared to the current payment rate under the Category III code of $3,353. Glaukos estimates that approximately 80% of procedures utilizing its trabecular micro-bypass technologies in the U.S. are performed in the ASC setting. For the remaining estimated 20% of procedures performed in the HOPD setting, the Proposed Rule includes a 2022 HOPD facility fee payment rate for CPT codes 669X2 and 669X1 of $4,019, compared to the current payment rate under the Category III code of $3,918. Additionally, the Proposed Rule includes a 2022 ASC facility fee payment rate for CPT code 01X2T, for standalone insertion of an aqueous drainage device, of $2,516 in the ASC setting and $2,131 in the HOPD setting, which would be the primary code that hospitals and ASCs will use to seek reimbursement utilizing Glaukos' iStent® infinite product, which is not yet approved by the U.S. Food & Drug Administration. The Proposed Rule and accompanying Addenda, including these proposed payment rates, can be accessed on the CMS website at www.cms.gov.

Glaukos Corporation plans to engage with CMS during the public comment period in hopes that medical facilities across its network are paid appropriately for conducting these types of procedures.

All website references herein are provided for convenience only and the content of the website does not constitute a part of this Current Report on Form 8-K. Further, the information contained herein shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses

All news about GLAUKOS CORPORATION
09/20GLAUKOS : Signs Licensing Deal With Attillaps
MT
09/20GLAUKOS : Announces Licensing Agreement with Attillaps Holdings, Inc.
BU
09/15Health Care Stocks Edge Higher Premarket Wednesday
MT
09/15GLAUKOS : Agrees to Stop Patent Litigation Against Ivantis in Exchange for $60 Million Pay..
MT
09/15GLAUKOS CORP : Other Events (form 8-K)
AQ
09/15GLAUKOS : Announces Settlement of Patent Litigation with Ivantis, Inc.
BU
09/03GLAUKOS : Says it Submitted Supplemental Pre-Market Approval Application for Investigation..
MT
09/03GLAUKOS : Announces Submission of Supplemental Pre-Market Approval Application for iStent ..
BU
09/03Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent..
CI
08/26GLAUKOS : Announces Participation in the Wells Fargo Healthcare Conference
BU
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Financials (USD)
Sales 2021 288 M - -
Net income 2021 -60,8 M - -
Net Debt 2021 75,9 M - -
P/E ratio 2021 -39,6x
Yield 2021 -
Capitalization 2 370 M 2 370 M -
EV / Sales 2021 8,48x
EV / Sales 2022 9,27x
Nbr of Employees 653
Free-Float 96,1%
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 50,93 $
Average target price 51,67 $
Spread / Average Target 1,45%
EPS Revisions
Managers and Directors
Thomas William Burns President, Chief Executive Officer & Director
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
William J. Link Chairman
L. Jay Katz Chief Medical Officer
Tomas Navratil Senior Vice President-Research & Development
Sector and Competitors